

To: [REDACTED] [REDACTED]@rivm.nl]; [REDACTED] [REDACTED]@rivm.nl]
From: [REDACTED]
Sent: Wed 4/8/2020 11:22:26 AM
Subject: FW: Extraordinary AF meeting Monday 6 April 13.00 CET
Received: Wed 4/8/2020 11:22:27 AM
[Use of face masks in the community.pdf](#)
[ECDC 8th RRA_AF.pdf](#)

Zie ecdc stuk over gebruik maskers

From: [REDACTED] <[REDACTED]@ecdc.europa.eu>
Sent: woensdag 8 april 2020 11:29
To: [REDACTED] <[REDACTED]@elisabethinen.or.at>; [REDACTED] <[REDACTED]@sam.lt>; [REDACTED] <[REDACTED]@vzbb.sk>; [REDACTED] <[REDACTED]@chl.lu>; [REDACTED] <[REDACTED]@iss.it>; [REDACTED] <[REDACTED]@ecdc.europa.eu>; [REDACTED] <[REDACTED]@santepubliquefrance.fr>; [REDACTED] <[REDACTED]@fhi.no>; [REDACTED] <[REDACTED]@gov.mt>; [REDACTED] <[REDACTED]@landlaeknir.is>; [REDACTED] <[REDACTED]@rki.de>; [REDACTED] <[REDACTED]@hse.ie>; [REDACTED] <[REDACTED]@nijz.si>; [REDACTED] <[REDACTED]@hzjz.hr>; [REDACTED] <[REDACTED]@szu.cz>; [REDACTED] <[REDACTED]@mphs.moh.gov.cy>; [REDACTED] <[REDACTED]@insa.min-saude.pt>; [REDACTED] <[REDACTED]@ssi.dk>; [REDACTED] <[REDACTED]@spkc.gov.lv>; [REDACTED] <[REDACTED]@insp.gov.ro>; [REDACTED] <[REDACTED]@tcd.ie>; [REDACTED] <[REDACTED]@pzh.gov.pl>; [REDACTED] <[REDACTED]@thl.fi>; [REDACTED] <[REDACTED]@msssi.es>; [REDACTED] <[REDACTED]@folkhalsomyndigheten.se>; [REDACTED] <[REDACTED]@rivm.nl>; [REDACTED] <[REDACTED]@sciensano.be>; [REDACTED] <[REDACTED]@nnk.gov.hu>; [REDACTED] <[REDACTED]@yahoo.com>; [REDACTED] <[REDACTED]@who.int>; [REDACTED] <[REDACTED]@ijzcg.me>
Cc: [REDACTED] <[REDACTED]@nnk.gov.hu>; [REDACTED] <[REDACTED]@agihas.lv>; [REDACTED] <[REDACTED]@ages.at>; [REDACTED] <[REDACTED]@thl.fi>; [REDACTED] <[REDACTED]@santepubliquefrance.fr>; [REDACTED] <[REDACTED]@arsnorte.min-saude.pt>; [REDACTED] <[REDACTED]@szu.cz>; [REDACTED] <[REDACTED]@mh.government.bg>; [REDACTED] <[REDACTED]@mphs.moh.gov.cy>; [REDACTED] <[REDACTED]@nijz.si>; [REDACTED] <[REDACTED]@jfmmed.uniba.sk>; [REDACTED] <[REDACTED]@bkus.lv>; [REDACTED] <[REDACTED]@inmi.it>; [REDACTED] <[REDACTED]@terviseamet.ee>; [REDACTED] <[REDACTED]@ssi.dk>; [REDACTED] <[REDACTED]@sam.lt>; [REDACTED] <[REDACTED]@folkhalsomyndigheten.se>; [REDACTED] <[REDACTED]@fhi.no>; [REDACTED] <[REDACTED]@isciii.es>; [REDACTED] <[REDACTED]@gov.mt>; [REDACTED] <[REDACTED]@rki.de>; [REDACTED] <[REDACTED]@sciensano.be>; [REDACTED] <[REDACTED]@pzh.gov.pl>; [REDACTED] <[REDACTED]@landlaeknir.is>; [REDACTED] <[REDACTED]@hzjz.hr>; [REDACTED] <[REDACTED]@rivm.nl>; [REDACTED] <[REDACTED]@ec.europa.eu>; [REDACTED] <[REDACTED]@ecdc.europa.eu>; [REDACTED] <[REDACTED]@ecdc.europa.eu>; [REDACTED] <[REDACTED]@ecdc.europa.eu>; [REDACTED] <[REDACTED]@ec.europa.eu>; [REDACTED] <[REDACTED]@ecdc.europa.eu>; PHE Manager <[REDACTED]@ecdc.europa.eu>

Subject: RE: Extraordinary AF meeting Monday 6 April 13.00 CET

Dear Colleagues

Further to our discussions in this week's extraordinary meeting of the Advisory Forum, I attach the 8th Update to the ECDC Rapid Risk Assessment on COVID-19 (to be published later today), along with the revised version of the document on face masks. In both, we have attempted to reflect the balance of the discussions in this week's meeting

Kind regards

[REDACTED]



[REDACTED]
 [REDACTED]
 SMS
 Phone: [REDACTED]
 [REDACTED]@ecdc.europa.eu

**European Centre for
 Disease Prevention and Control (ECDC)**

Gustav III:s boulevard 40, 169 73 Solna, Sweden
 Phone +46 (0)8 58 60 10 00 / Fax +46 (0)8 58 60 10 01
www.ecdc.europa.eu

Follow ECDC on:    

From: 5.1.2e
Sent: 04 April 2020 10:56
To: 5.1.5; 5.1.2e @ecdc.europa.eu>; 5.1.2e
 < 5.1.2e @elisabethinen.or.at>; 5.1.2e < 5.1.2e @sam.lt>; 5.1.2e < 5.1.2e @vzbb.sk>; 5.1.2e
 < 5.1.2e @chl.lu>; 5.1.2e < 5.1.2e @iss.it>; 5.1.2e < 5.1.2e @santepubliquefrance.fr>; 5.1.2e < 5.1.2e @fhi.no>; 5.1.2e < 5.1.2e @gov.mt>;
 5.1. 5.1.2e < 5.1.2e @landlaeknir.is>; 5.1.2e < 5.1.2e @rki.de>; 5.1.2e < 5.1.2e @hse.ie>;
 5.1.2e < 5.1.2e @nijz.si>; 5.1.2e < 5.1.2e @hzjz.hr>; 5.1.2e < 5.1.2e @szu.cz>; 5.1.2e
 5.1.2e < 5.1.2e @mphs.moh.gov.cy>; 5.1.2e < 5.1.2e @insa.min-saude.pt>; 5.1.2e < 5.1.2e @ssi.dk>;
 5.1.2e < 5.1.2e @spkc.gov.lv>; 5.1.2e < 5.1.2e @insp.gov.ro>; 5.1.2e
 < 5.1.2e @tcd.ie>; 5.1.2e < 5.1.2e @pzh.gov.pl>; 5.1.2e < 5.1.2e @thl.fi>; 5.1.2e
 5.1.2e < 5.1.2e @msssi.es>; 5.1.2e < 5.1.2e @folkhalsomyndigheten.se>; 5.1.2e < 5.1.2e @rivm.nl>;
 5.1.2e < 5.1.2e @med.uoa.gr>; 5.1.2e < 5.1.2e @rivm.nl>; 5.1.2e
 < 5.1.2e @sciensano.be>; 5.1.2e < 5.1.2e @nnk.gov.hu>; 5.1.2e
 < 5.1.2e @yahoo.com>; 5.1.2e < 5.1.2e @who.int>; 5.1.2e < 5.1.2e @ijzcg.me>
Cc: 5.1.2e < 5.1.2e @nnk.gov.hu>; 5.1.2e < 5.1.2e @agihass.lv>; 5.1.2e < 5.1.2e @ages.at>;
 5.1.2e < 5.1.2e @thl.fi>; 5.1.2e < 5.1.2e @santepubliquefrance.fr>; 5.1.2e
 5.1.2e < 5.1.2e @arsnorte.min-saude.pt>; 5.1.2e < 5.1.2e @szu.cz>; 5.1.2e
 < 5.1.2e @mh.government.bg>; 5.1.2e < 5.1.2e @mphs.moh.gov.cy>; 5.1.2e < 5.1.2e @nijz.si>;
 5.1.2e < 5.1.2e @jfmed.uniba.sk>; 5.1.2e < 5.1.2e @bkus.lv>; 5.1.2e
 < 5.1.2e @inmi.it>; 5.1.2e < 5.1.2e @terviseamet.ee>; 5.1.2e < 5.1.2e @ssi.dk>; 5.1.2e
 < 5.1.2e @sam.lt>; 5.1.2e < 5.1.2e @folkhalsomyndigheten.se>; 5.1.2e < 5.1.2e @fhi.no>; 5.1.2e
 5.1.2e < 5.1.2e @isciii.es>; 5.1.2e < 5.1.2e @gov.mt>; 5.1.2e < 5.1.2e @rki.de>; 5.1.2e
 5.1.2e < 5.1.2e @sciensano.be>; 5.1.2e < 5.1.2e @pzh.gov.pl>; 5.1.2e
 < 5.1.2e @landlaeknir.is>; 5.1.2e < 5.1.2e @hzjz.hr>; 5.1.2e
 < 5.1.2e @rivm.nl>; 5.1.2e < 5.1.2e @ec.europa.eu>; 5.1.2e
 < 5.1.2e @ecdc.europa.eu>; 5.1.2e < 5.1.2e @ecdc.europa.eu>; 5.1.2e
 < 5.1.2e @ecdc.europa.eu>; 5.1.2e < 5.1.2e @ecdc.europa.eu>; 5.1.2e @ec.europa.eu'
 < 5.1.2e @ec.europa.eu>; 5.1.2e < 5.1.2e @ecdc.europa.eu>; 5.1.5 5.1.2e @ecdc.europa.eu>

Subject: RE: Extraordinary AF meeting Monday 6 April 13.00 CET

Dear Colleagues

Please find attached the draft agenda and a PowerPoint presentation that outlines the structure and content of ECDC's next Rapid Risk Assessment on COVID-19. This is the background document for our discussions in Monday's extraordinary meeting of the Advisory Forum.

In addition, I attach a copy of ECDC's surveillance strategy, which was also circulated prior to the previous extraordinary meeting of the Advisory Forum. With regards to this document, please note that in our discussion on Monday we should focus on scenario 2-4 and in particular on the need to ensure that primary care and secondary care surveillance systems continue to report cases of ARI/ILI and SARI, testing a systematic number of them, in order to derive incidence data and to monitor trends. We are working on a simplified version of the strategy with a focus on the current epidemiologic situation of widespread transmission in all countries, which will be disseminated later, but the key points in that will not differ from the attached document.

Kind regards

5.1.2e

5.1.2e
Dubbel

3 - 5

Dubbel